DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
DENTSPLY SIRONA Inc. executive Andrea L. Frohning, SVP and CHRO, reported a disposition of 802 shares of common stock on 2026-08-07. The shares were withheld to cover taxes related to the vesting of previously reported Restricted Stock Units and dividend equivalent units. After this tax-withholding event, Frohning directly holds 63,190.618 shares of common stock, a figure updated for rounding effects from dividend payments.
Dentsply Sirona Inc. corrected a technical SEC description tag in a prior report and announced financial results for the quarter ended June 30, 2026. Net sales were $898 million, down 4.1% year over year, while GAAP gross margin improved to 54.9%. Net income attributable to the company was $37 million, or $0.18 per diluted share, compared with a prior-year loss.
On a non-GAAP basis, adjusted EBITDA was $190 million with a 21.3% margin and adjusted EPS held at $0.52. Operating cash flow rose to $99 million and free cash flow to $55 million, supported by approximately $44 million of tariff refunds, and the company repurchased 1.3 million shares for about $12 million. Management reaffirmed 2026 guidance for net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50.
First Eagle Investment Management, LLC filed an amended Schedule 13G reporting beneficial ownership of 851,347 shares of DENTSPLY SIRONA Inc. common stock. This represents 0.4% of the class as of the reporting date.
First Eagle has sole voting power over 659,032 shares and sole dispositive power over 851,347 shares, with no shared voting or dispositive power. The filer notes that its stake represents ownership of 5 percent or less of the class.
Dentsply Sirona reported Q2 2026 net sales of $898 million, down 4.1% year over year, or 6.3% in constant currency. GAAP gross margin improved to 54.9% from 52.4%. Net income attributable to Dentsply Sirona was $37 million versus a prior-year loss of $45 million, with diluted EPS of $0.18 compared with a loss of $0.22.
On a non-GAAP basis, adjusted gross margin was 56.4%, adjusted EBITDA was $190 million with a 21.3% margin, and adjusted EPS was $0.52, unchanged from Q2 2025. Operating cash flow rose to $99 million, including about $44 million of tariff refunds, and free cash flow was $55 million. The company repurchased 1.3 million shares for approximately $12 million and ended June 30, 2026 with $239 million of cash and cash equivalents and long-term debt of $1,996 million. Management reiterated its 2026 outlook for net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50, excluding tariff refunds from adjusted EPS guidance.
DENTSPLY SIRONA Inc. identifies John C. Fortson, Executive Vice President and Chief Financial Officer, as a reporting insider through an initial ownership report. The filing shows no equity transactions or holdings and notes an attached Exhibit 24 Power of Attorney authorizing certain filing-related actions.
BlackRock, Inc. reported beneficial ownership of 25,295,015 shares of DENTSPLY SIRONA INC common stock, representing 12.6% of the class as of 06/30/2026. The filing shows sole voting power over 24,804,969 shares and sole dispositive power over 25,295,015 shares.
MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky received a compensation grant of phantom stock units tied to the company’s common stock. On this Form 4, he was awarded 2,841.8303 shares of phantom stock at $10.56 per share, each economically equivalent to one share of common stock. Following this award, his total phantom stock balance is 20,021.6843 units, which will be settled in common stock after his service as a director ends. This is a non-cash, deferred compensation transaction rather than an open-market stock purchase or sale.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky filed an amended insider report clarifying that a recent transaction was an open-market stock purchase. On this amended Form 4, he is shown buying 10,000 shares of common stock at $10.14 per share. Following this transaction, his direct ownership stands at 61,668.534 shares of DENTSPLY SIRONA common stock. The amendment corrects the original coding of the trade, which had been mistakenly reported as an award rather than a market purchase, while leaving all other details unchanged.
DENTSPLY SIRONA Inc. executive Lindi Rene Barton-Brobst, SVP, GC & Secretary, filed an initial statement of beneficial ownership. She reports 45,185.444 shares of common stock held directly, including 38,743.444 Restricted Stock Units, plus 254.6498 shares held indirectly through a 401(k) plan.
She also holds phantom stock representing 556.7220 equivalent common shares under a Supplemental Executive Retirement Plan, payable in stock upon termination of employment, and multiple stock option grants to buy common shares at exercise prices between $14.7800 and $58.7100 with expirations from 2030 to 2036. The filing lists these positions as holdings rather than reporting new purchases or sales.